title: INTRAVITREAL BEVACIZUMAB IN THE TREATMENT OF CHOROIDAL NEOVASCULAR MEMBRANE DUE TO ANGIOID STREAKS.
abstract: OBJECTIVE
  To investigate the results of intravitreal bevacizumab for choroidal neovascularization (CNV) secondary to angioid streaks and to assess the factors influencing disease progression.
  
  
  METHODS
  Patients treated with intravitreal bevacizumab (1.25 mg/0.05 mL) for CNV secondary to angioid streaks were reviewed retrospectively. In addition to demographic findings, ophthalmologic findings at baseline and during follow-ups were recorded.
  
  
  RESULTS
  Twenty-three eyes of 20 patients (mean age, 45.7 years; 7 women) were included in the study. Mean follow-up was 23 months. Mean number of injections was 5.1. Initial and final logMAR visual acuity was not different (0.53 ± 0.33 and 0.60 ± 0.40 logMAR, P = 0.79). At the last examination, patients with final active CNV (N = 14) were younger (mean age, 42 years) than patients with final inactive CNV (N = 9) (mean age, 52 years). The former group required higher number of injections (6.6 vs. 2.8, P = 0.013). Eyes with pseudoxanthoma elasticum (N = 10) needed injections every 4.4 months while the others (N = 13) every 7.2 months (P = 0.072). Pseudoxanthoma elasticum positivity ended up with active membranes in 70% of the cases, composing half of the overall final active CNVs in this study.
  
  
  CONCLUSIONS
  Intravitreal bevacizumab stabilized vision in eyes with CNV and angioid streaks. At younger ages, CNV behaved more aggressively and seemed to be more resistant to treatment.
authors.affiliation: *Beyoğlu Eye Research and Training Hospital, Istanbul, Turkey; †Gaziosmanpaşa Taksim Training and Research Hospital, Istanbul, Turkey; and ‡Department of Ophthalmology, Marmara University Medical School, Istanbul, Turkey.
authors.forename: Cengiz
authors.initials: C
authors.lastname: Alagöz
authors.forename: Neşe
authors.initials: N
authors.lastname: Alagöz
authors.forename: Abdullah
authors.initials: A
authors.lastname: Özkaya
authors.forename: Uğur
authors.initials: U
authors.lastname: Çelik
authors.forename: Miray F
authors.initials: MF
authors.lastname: Turan
authors.forename: Ahmet T
authors.initials: AT
authors.lastname: Yazici
authors.forename: Osman
authors.initials: O
authors.lastname: Çekiç
authors.forename: Ahmet
authors.initials: A
authors.lastname: Demirok
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000793:Angioid Streaks / Q000150:complications*; D000068258:Bevacizumab / Q000627:therapeutic use*; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D011561:Pseudoxanthoma Elasticum / Q000150:complications; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000187:drug effects / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab